ClinicalTrials.gg
Active, not recruitingNCT06185426facial nerveUpdated Jan 3, 2024

Histopathological, Biochemical And Electrophysiological Evaluation Of Single Or Combined Use Of Diode Laser/Steroid Treatment On Facial Nerve Injury

An Early Phase 1 interventional study of Methyprednisolon and low level laser theraphy in Nerve Injury, Laser Therapy and Methylprednisolone, sponsored by Recep Tayyip Erdogan University. Active, not recruiting at 1 site in Turkey. Open to male participants aged 4 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Recep Tayyip Erdogan University · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Jan 2021, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
4 Months to 6 Months
Sex
Male
01

Study summary

The objective of the study will be to investigate the effect of low-level diode laser therapy (LLLT) and steroid on facial nerve injury. Thirty five male Wistar rat will randomly be divided into five groups: healthy control (HCG); damage control (DC); laser (LG); steroid (SG); and combined laser and steroid group (LSG). Right facial nerve electromyography (EMG) data will record after facial nerve damage done and before sacrification at 4th week.The results will be evaluated histopathologically, electrophysiologically and biochemically.

Read the detailed description

The animals will be randomly divided into two control groups, a healthy control group and a damaged control group, and three experimental groups; 7 rats were assigned to each group as follows;

  1. Healthy Control Group (HCG): Seven rats will be included randomly in this group. No surgical/medical approach will be applied. EMG measurements will betaken over the right facial nerve.
  2. Damaged Control Group (DCG): Facial nerve injury will be created on the right facial nerve. No surgical/medical approach will be applied. EMG measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment.
  3. Laser Group (LG): Facial nerve injury will be created on the right facial nerve. LLLT (Low-Intensity et al.) will be applied 3 times a week for 4 weeks postoperatively, at 830 nm with an optical power output of 30 mW, an energy density of 4 J/cm2, an irradiation area of 0.116 cm2 and an exposure time of 16 s per spot. EMG measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment.
  4. Steroid group (SG): Facial nerve injury will be created on the right facial nerve. Intraperitoneal methylprednisolone (1mg/kg/day) will be administered every day for 1 week postoperatively. EMG measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment.
  5. Laser+Steroid Group (LSG): Facial nerve injury will be created on the right facial nerve. Laser and steroid treatment will be applied in combination. EMG measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment.
02

Conditions studied

  • Nerve Injury
  • Laser Therapy
  • Methylprednisolone
  • Facial Nerve Injuries

Keywords

  • Facial Nerve Injury
  • Steroid
  • Low Level Laser Therapy
  • Nerve Recovery
03

In context

Lead sponsor

Recep Tayyip Erdogan University is the lead sponsor of 69 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Months to 6 Months
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Thirty-five male Sprague-Dawley rats weighing 200-300 g will be included the study

Exclusion criteria

Exclusion Criteria:

-Rats that are older than 6 months and are not healthy and have impaired facial motor functions will be excluded from the study.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Placebo comparator
    Healthy Control Group (HCG)

    Seven rats will be included randomly in this group. No surgical/medical approach will be applied.

    Drug: Methyprednisolon and low level laser theraphy

  • Active comparator
    Damaged Control Group (DCG):

    Facial nerve injury will be created on the right facial nerve. No surgical/medical approach will be applied.

    Drug: Methyprednisolon and low level laser theraphy

  • Experimental
    Laser Group (LG)

    Facial nerve injury will be created on the right facial nerve. LLLT (Low-Intensity et al.) willl be applied 3 times a week for 4 weeks postoperatively, at 830 nm with an optical power output of 30 mW, an energy density of 4 J/cm2, an irradiation area of 0.116 cm2 and an exposure time of 16 s per spot.

    Drug: Methyprednisolon and low level laser theraphy

  • Experimental
    Steroid group (SG)

    Facial nerve injury will be created on the right facial nerve. Intraperitoneal methylprednisolone (1mg/kg/day) will be administered every day for 1 week postoperatively.

    Drug: Methyprednisolon and low level laser theraphy

  • Experimental
    Laser+Steroid Group (LSG):

    Facial nerve injury will be created on the right facial nerve. Laser and steroid treatment will be applied in combination.

    Drug: Methyprednisolon and low level laser theraphy

Interventions

  • DrugMethyprednisolon and low level laser theraphy

    All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.

06

What researchers measure

Primary outcomes

  1. Electromyographic Analysis

    Measuring the amplitude and latency of the action potential occurring in the nerve with electromyography(On facial nerve)

    Time frame: 1 month

Secondary outcomes

  1. Biochemical Analysis

    Determination of MDA and GSH levels in blood samples taken

    Time frame: 1 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jun 2023, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 29, 2023
StartActual
Jan 1, 2021
Primary completionActual
Jun 1, 2023
CompletionEst.
Feb 1, 2024
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06185426
Lead sponsor
Recep Tayyip Erdogan University
Responsible party
Zeynep Gumrukcu (associate professor, Recep Tayyip Erdogan University) — Principal investigator
First posted
Dec 29, 2023
Start date
Jan 1, 2021
Primary completion
Jun 1, 2023
Completion
Feb 1, 2024 (estimated)
Last update
Jan 3, 2024

Study contacts

zeynep gümrükçü, Associate Professor
study director · RTEU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion